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Background: Risk stratification in individuals with type 2 diabetes (T2D) remains an important priority in the
management of associated morbidity and mortality, including from cardiovascular disease (CVD). The current
investigation examined whether estimated glomerular filtration rate (eGFR) and urine albumin:creatinine ratio
(UACR) were independent predictors of CVD-mortality in European Americans (EAs) with T2D after accounting for
subclinical CVD.
Methods: The family-based Diabetes Heart Study (DHS) cohort (n=1,220) had baseline measures of serum
creatinine, eGFR, UACR and coronary artery calcified plaque (CAC) assessed by non-contrast computed tomography
scan. Cox proportional hazards regression was performed to determine risk for all-cause mortality and CVD-mortality
associated with indices of kidney disease after accounting for traditional CVD risk factors and CAC as a measure of
subclinical CVD.
Results: Participants were followed for 8.2±2.6 years (mean±SD) during which time 247 (20.9%) were deceased, 107
(9.1%) from CVD. Univariate analyses revealed positive associations between serum creatinine (HR:1.56; 95% CI:
1.37–1.80; p<0.0001) and UACR (1.59; 1.43–1.77; p>0.0001) and negative associations between serum albumin
(0.74; 0.65–0.84; p<0.0001) and eGFR (0.66; 0.58–0.76; p<0.0001) with all-cause mortality. Associations remained
significant after adjustment for traditional CVD risk factors, as well as for CAC. Similar trends were noted when
predicting risk for CVD-mortality.
Conclusions: The DHS reveals that kidney function and albuminuria are independent risk factors for all-cause
mortality and CVD-mortality in EAs with T2D, even after accounting for CAC.
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Cardiovascular disease (CVD) remains a serious compli-
cation in individuals with type 2 diabetes (T2D), ac-
counting for greater than 60% of all-cause mortality [1].
However, not all individuals with T2D experience the same
risk for macrovascular disease and other complications [2];
this variable risk likely reflects different underlying environ-
mental and inherited risk factors, diabetes duration, extent
of subclinical CVD, and clinical management. As such, risk* Correspondence: dbowden@wakehealth.edu
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reproduction in any medium, provided the orstratification remains an important priority in the preven-
tion of T2D-associated morbidity and mortality.
The Diabetes Heart Study (DHS) is a family-based
study enriched for T2D affected individuals. Recent find-
ings from the DHS have shown that coronary artery
calcified plaque (CAC) determined by non-invasive,
non-contrast computed tomography (CT) scanning and
accepted as reflecting subclinical CVD, is an independ-
ent predictor of both all-cause mortality [3] and CVD-
mortality [4]. Observed odds ratios for CAC scores
exceeding 1000 were 6.7–11.2 [3]. In an effort to further
refine these models, we have investigated whether other
non-invasive clinical measures were independent predictors. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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for CAC.
Reduction in kidney function (or estimated glomerular
filtration rate; eGFR) is an established risk factor for
adverse CVD outcomes in a range of settings, including
acute coronary syndrome [5], heart failure [6,7] and
acute myocardial infarction [8]. However, uncertainty
remains as to direct causality and the mechanisms
underpinning relationships between kidney function and
CVD [9,10]. In addition, although a range of renal func-
tion indices are associated with CVD-mortality in both
population-based studies [11,12] and T2D-affected
cohorts [13-15], adjustment for underlying vascular
disease burden is frequently overlooked. We have previ-
ously reported strong independent associations between
albuminuria and CAC in the DHS [16]. Likewise,
microalbuminuria has also been associated with increased
presence and progression of CAC in the Multi-Ethnic
Study of Atherosclerosis [17] as well as with increased ca-
rotid intima-media thickness, another measure of subclin-
ical CVD [18]. Given the potential interplay between
kidney function, endothelial dysfunction, atherosclerotic
plaque formation and CVD outcomes, this investigation
examined whether measures of kidney function and
albuminuria were predictive of mortality in European
Americans (EAs) with T2D, independent of CAC.
Methods
Study design and sample
The DHS cohort includes 1,220 self-described EA indi-
viduals from 475 families. Briefly, the DHS recruited sib-
lings concordant for T2D without advanced renal
insufficiency, manifesting as serum creatinine concentra-
tion >2 mg/dL, or end-stage renal disease. When pos-
sible, one non-T2D affected sibling was also recruited.
T2D was clinically defined as diabetes developing after
the age of 35 years and actively treated with insulin and/
or oral agents, in the absence of historical evidence of
ketoacidosis. Diagnoses were confirmed by baseline meas-
urement of fasting blood glucose and glycosylated
hemoglobin (HbA1C). Full ascertainment and recruitment
criteria have been previously described in detail [19,20].
Study protocols were approved by the Institutional
Review Board at Wake Forest School of Medicine, and
all participants provided written informed consent
prior to participation. Participant examinations were
conducted in the Clinical Research Unit of Wake
Forest Baptist Medical Center, and included interviews
for medical history (including self-reported history of
prior CVD events or intervention) and health behav-
iors, anthropometric measures, resting blood pressure,
electrocardiography, fasting blood sampling for laboratory
analyses including fasting glucose, HbA1C, lipids, serum al-
bumin and creatinine concentration. Estimated GFR wascalculated using the 4-variable Modification of Diet in
Renal Disease (MDRD) equation [21]. A spot urine collec-
tion was obtained for determination of urine albumin:
creatinine ratio (UACR).
Coronary artery calcified plaque (CAC) was measured
using fast-gated helical CT scanners, with calcium scores
calculated as previously described [22,23]. CAC is widely
accepted as reflecting the burden of subclinical CVD.
Mortality
Vital status was determined for all participants from the
National Social Security Death Index maintained by the
United States Social Security Administration. For partici-
pants confirmed as deceased, length of follow-up was
determined from the date of the initial study visit to date
of death. For deceased participants, copies of death
certificates were obtained from relevant county Vital
Records Offices to confirm cause of death. For all other
participants the length of follow-up was determined
from the date of the initial study visit to the end of 2011.
Cause of death was categorized based on information
contained in death certificates as CVD-related (myocardial
infarction, congestive heart failure, cardiac arrhythmia,
sudden cardiac death, peripheral vascular disease, and
stroke), cancer, infection, end-stage renal disease, acciden-
tal, or other (including obstructive pulmonary disease,
pulmonary fibrosis, liver failure and Alzheimer’s dementia).
Statistical analysis
Summary statistics were calculated including means and
standard deviations (SD), medians and ranges for continu-
ous variables, and count and percentages for categorical
variables. Continuous variables were transformed prior to
analysis to approximate normality. To evaluate the associ-
ation of serum albumin, serum creatinine, UACR and eGFR
with all-cause mortality and CVD-mortality a survival ana-
lysis was used. Variables reflecting kidney disease and
serum albumin were considered as both ordinal (Q1-4
derived from increasing quartile ranges) and continuous
variables. In order to compare the relative importance,
kidney disease (continuous) variables were standardized for
analysis of associations with outcome.
Curves of cumulative incidence of both all-cause mor-
tality and CVD-mortality for increasing quartiles of each
of the kidney disease measures were plotted for explora-
tory analyses (Additional file 1: Figures S1-S4). Due to
the inclusion of related individuals in the DHS, Cox pro-
portional hazards models with sandwich-based variance
estimation were used to examine the relationships be-
tween measures of kidney disease and both all-cause
mortality and CVD-mortality. Initially an exploratory
test for trend across increasing quartiles of the measures
of kidney disease was performed to examine relation-
ships with all-cause and CVD-mortality. Analyses of the
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were then performed. Each of these associations was
subsequently adjusted for (i) age, sex, T2D affection status
and use of angiotensin-converting enzyme (ACE) inhibitor
and angiotensin-receptor blocker (ARB) medications
(partially adjusted) and (ii) age, sex, T2D affection
status, ACE/ARB medication use, body mass index
(BMI), current smoking, hypertension, dyslipidemia,
and self-reported history of prior CVD (fully
adjusted). To assess whether measures of kidney dis-
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Coronary artery calcified plaque (Agatston units)CVD the fully adjusted models were further adjusted
for CAC.
Receiver operating characteristic (ROC) curves were
computed for models containing traditional CVD risk
factors (as used in fully adjusted models above) and with
addition of either a measure of kidney disease, CAC, or
both kidney disease measures and CAC. The areas
under the curves were used to assess the ability of
measures of kidney disease to predict all-cause mortal-
ity or CVD-mortality after adjusting for traditional
CVD risk-factors and CAC. The difference in areaAmerican Diabetes Heart Study (DHS) participants
Mean ± SD or % Median (range)
62.0 ± 9.3 62.6 (35–86)
53.3%
83.7%





168.6 ± 9.7 168.4 (122.8–202.0)
90.6 ± 20.2 88.3 (40.0–209.2)
31.8 ± 6.5 30.8 (16.6–58.0)
44.7%
44.7%
139 ± 19 138 (70–260)
73 ± 10 73 (37–106)
84.9%
139.3 ± 55.3 126 (16–463)
7.3 ± 1.7 6.9 (3.5–18.3)
186.8 ± 42.3 183 (65–427)
43.1 ± 12.4 41 (8–104)
105.2 ± 32.6 103 (12–236)
200.9 ± 131.6 172 (30–1310)
4.2 ± 0.3 4.2 (3.2–5.3)
1.08 ± 0.25 1.10 (0.40–1.75)
67.1 ± 20.2 64.3 (20.0–179.9)
91.1 ± 319.9 12.4 (0.5–4165.0)
1657 ± 3148 330 (0–50415)
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Delong’s method [24].
All analyses were performed using SAS version 9.2
(SAS Institute Inc., Cary, NC) with the exception of the
ROC analyses which were performed using Stata soft-
ware, version 12.1 (StataCorp, College Station, TX).
Statistical significance was accepted at p<0.05.Results
Demographic and clinical characteristics of the DHS co-
hort are presented in Table 1. As anticipated in a T2D-
enriched sample, a predominance of traditional CVD
risk factors were evident including high BMI, hyperten-
sion, dyslipidemia and prior CVD events. Scores for
CAC reflect a substantial burden of subclinical CVD in
these diabetes-affected individuals and their siblings.
Measurements of proteinuria and kidney function in the
DHS revealed 27.9% with UACR >30 mg/g and 38.5%
with eGFR<60ml/min/1.73m2. The cohort was followed
for 8.2 ± 2.6 years (mean ± SD) during which time 247
(20.9%) participants were deceased, 107 (9.1%) from
CVD causes.
Cumulative incidence for all-cause and CVD-mortality
increased with increasing serum creatinine and UACR
and decreasing serum albumin and eGFR (Additional file
1: Figures S1-S4). A formal test for trend using ordinal
measures (derived from quartile cut-points) supported
an overall trend for increasing creatinine (HR: 1.42; 95%
CI: 1.26–1.60; p=2.74×10-7) and UACR (HR: 1.55; 1.37–
1.74; p=1.18×10-12) and decreasing serum albumin (HR:
0.82; 95% CI: 0.73–0.92; p=0.0005) and eGFR (HR: 0.71;
0.63–0.81; p=1.07×10-7) to be associated with risk for all-
cause mortality. Serum creatinine (HR: 1.55; 1.28–1.88;
p=6.51×10-6), UACR (HR: 1.87; 1.55–2.26; p=1.10×10-10)Table 2 Association between continuous measures of kidney
indicated
Unadjusted Partially adjuste
HR (CI) p-value HR (CI) p
All-cause m
Serum Albumin 0.74 (0.65–0.84) 7.13×10-6 0.72 (0.63–0.83) 3.
Serum Creatinine 1.56 (1.37–1.80) 1.53×10-10 1.32 (1.12–1.54) 0
UACR 1.59 (1.43–1.77) 1.48×10-20 1.48 (1.31–1.67) 1.6
eGFR 0.66 (0.58–0.76) 2.54×10-9 0.76 (0.65–0.89) 0
CVD mo
Serum albumin 0.81 (0.66–0.99) 0.04 0.80 (0.65–0.98)
Serum creatinine 1.76 (1.42–2.19) 3.29×10-7 1.52 (1.19–1.96) 0
UACR 1.79 (1.55–2.07) 4.00×10-15 1.65 (1.39–1.95) 4.
eGFR 0.62 (0.50–0.77) 1.08×10-5 0.69 (0.54–0.88)
UACR=urine albumin:creatinine ratio; eGFR=estimated glomerular filtration rate.
*adjusted for age, sex, type 2 diabetes affection status, ACE/ARB medication use; †
smoking, hypertension, dyslipidemia, ACE/ARB medication use, prior cardiovascularand eGFR (HR: 0.69; 0.58–0.83; p=5.86×10-5) were similarly
associated with risk for CVD-mortality. This trend was less
prominent for serum albumin (HR: 0.85; 0.71–1.02;
p=0.09). Similar patterns were noted when analyses
were repeated including T2D affected individuals only
(Additional file 1: Table S1).
Univariate analyses of continuous measures of kidney
disease further supported the positive association of
serum creatinine and UACR with all-cause and CVD-
mortality (Table 2). Each SD increase in these measures
was associated with ~1.5 fold (all-cause mortality) and
~1.75 fold (CVD-mortality) increase in risk, respectively.
These positive associations remained significant after ad-
justment for traditional CVD risk factors including T2D
affection status, BMI, current smoking, hypertension,
dyslipidemia, and prior CVD (Table 2). Similarly, univar-
iate analyses supported the negative associations of
serum albumin and eGFR with mortality outcomes. Each
SD increase in these measures was associated with a 25–
35% (all-cause) and a 20–40% (CVD-mortality) reduc-
tion in risk respectively. These negative associations also
remained significant after adjustment for traditional
CVD risk factors (Table 2). Results were essentially un-
changed when analyses were repeated including T2D af-
fected individuals only (Additional file 1: Table S2).
For each measure of kidney disease, fully adjusted
models were further adjusted for CAC. Measures of pro-
teinuria and kidney disease remained significantly associ-
ated with all-cause and CVD-mortality after additional
adjustment (Table 2). Using quartile ranges to define
high-risk individuals as those with serum creatinine and
UACR values in the highest quartile and serum albumin
and eGFR values in the lowest quartile of each respective
distribution, these analyses revealed that high-risk indi-
viduals were at 1.4–1.8 fold increased risk for all-causedisease and mortality with covariate adjustment as
d* Fully adjusted† Fully adjusted† + CAC
-value HR (CI) p-value HR (CI) p-value
ortality
80×10-6 0.71 (0.61–0.82) 4.02×10-6 0.71 (0.61–0.82) 6.81×10-6
.0007 1.28 (1.10–1.50) 0.002 1.29 (1.10–1.52) 0.002
6×10-10 1.41 (1.25–1.59) 3.95×10-8 1.37 (1.22–1.56) 3.83×10-7
.0006 0.77 (0.66–0.90) 0.001 0.77 (0.65–0.91) 0.002
rtality
0.03 0.77 (0.62–0.95) 0.02 0.78 (0.63–0.98) 0.03
.0009 1.44 (1.13–1.84) 0.003 1.48 (1.15–1.91) 0.003
74×10-9 1.54 (1.29–1.83) 1.32×10-6 1.50 (1.26–1.79) 5.22×10-6
0.002 0.71 (0.56–0.91) 0.006 0.69 (0.53–0.89) 0.005
adjusted for age, sex, type 2 diabetes affection status, body mass index, current
disease.
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CVD-mortality (Table 3). Results were essentially un-
changed when analyses were repeated including T2D af-
fected individuals only (Additional file 1: Table S3).
Area under the curve analysis confirmed the utility of
serum albumin in the prediction of all-cause mortality
(AUC: 0.73 to 0.75; p=0.008) and of UACR in the predic-
tion of CVD-mortality (AUC: 0.74 to 0.77; p=0.03) when
included in models containing traditional risk factors. In
contrast, serum creatinine and eGFR did not improve
prediction beyond traditional risk factors (Additional file
1: Table S4). The tendency for serum albumin and
UACR to improve prediction of all-cause (AUC: 0.73 to
0.78; p=0.02) and CVD-mortality (AUC: 0.74 to 0.80;
p=0.06) respectively was still evident, although to a
lesser extent in the models including CAC.Discussion
Cardiovascular complications and CVD-mortality are in-
creased in individuals with T2D. As such, improved risk
prediction may lead to reductions in morbidity and pre-
mature mortality. We previously demonstrated that al-
buminuria was positively associated with CAC in the
T2D-enriched DHS cohort [16] and that CAC power-
fully predicted mortality in this sample [3,4]. We now
extend these observations by demonstrating that pro-
teinuria and eGFR remained predictive of all-cause mor-
tality and CVD-mortality after accounting for the
presence of traditional CVD risk factors and CAC. CAC
is known to be associated with reduced eGFR and albu-
minuria. As such, it remained important to demonstrate
that measures of kidney disease were independently as-
sociated with mortality even after subclinical CVD was
accounted for in the analyses. To date, relatively few
studies have assessed mortality after a mean eight yearTable 3 Association between categorical measures of kidney
(CVD) mortality
Quartiles Quartlie ranges HR
Serum albumin† Q1-Q3 3.2–4.4
1.54
Q4 4.4–5.3









UACR=urine albumin:creatinine ratio; eGFR=estimated glomerular filtration rate.
Associations based on proportional hazards regression models adjusted for age, sex
hypertension, dyslipidemia, ACE/ARB medication use, prior CVD and coronary artery
*For serum creatinine and UACR, quartiles were established based on increasing va
individuals. †For serum albumin and eGFR, quartiles were established based on dec
risk individuals.follow-up based on the independent effects of CAC and
parameters of kidney disease.
That measures of kidney disease predicted mortality in
a T2D-enriched sample is broadly consistent with the
existing literature. A number of investigations have iden-
tified the associations of both albuminuria with CVD-
mortality and eGFR with CVD-mortality, consistently
demonstrating that these were independent associations
[11-14,25,26]. Albuminuria and eGFR have also been
confirmed to predict all-cause mortality in a recent large
meta-analysis using general population cohorts of vary-
ing ethnicities [27]. An additional meta-analysis utilizing
cohorts with multiple underlying CVD risk factors
reported that both UACR and eGFR predicted mortality
independent from traditional CVD risk factors [26]. Al-
though some of these investigations accounted for trad-
itional CVD risk factors and history of prior CVD, the
present DHS analysis demonstrates that measures of
kidney function and UACR remained independently as-
sociated with all-cause mortality and CVD-mortality
after accounting for traditional CVD risk factors and
CAC [4]. This was a critical analysis due to the relation-
ships between UACR, eGFR and CAC and further sup-
ports the utility of these common clinical indices in risk
stratification.
In this report, all predictor variables were standardized
to allow for direct comparison of the relative importance
of each in the context of risk for mortality. Based on cal-
culated HR, UACR was the strongest predictor of all-
cause mortality and CVD-mortality in the DHS after
accounting for traditional CVD risk factors. Following
additional adjustment for CAC, the HR suggested risk
for both all-cause and CVD-mortality was greatest
among those in the highest quartile of the measured
UACR distribution. In the DHS, the upper quartile for
serum creatinine concentration and UACR and thedisease and all-cause mortality and cardiovascular disease
All-cause mortality CVD-mortality
(95% CI) p-value HR (95% CI) p-value
(1.14–2.08) 0.005 1.35 (0.84–2.17) 0.21
(0.99–1.87) 0.06 2.02 (1.24–3.29) 0.005
(1.38–2.39) 1.99×10-5 2.38 (1.61–3.53) 1.50×10-5
(1.16–2.16) 0.004 1.94 (1.23–3.05) 0.004
, type 2 diabetes affection status, body mass index, current smoking,
calcified plaque.
lues across the distribution such that quartile 4 (Q4) captures the highest risk
reasing values across the distribution such that Q4 again captures the highest
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criteria for impairment of kidney function; UACR may per-
form differently in populations where renal function is bet-
ter preserved. That said, UACR [25] and urine albumin
excretion [14] have been reported to be stronger predictors
of CVD-mortality than eGFR in subjects with T2D. Further,
while proteinuria and eGRF were found to independently
predict all-cause and CVD-mortality in the Taichung Dia-
betes Study, in this case investigators concluded that eGFR
alone may be inadequate for risk prediction in T2D and
that consideration of proteinuria can provide additional
useful information [28]. The findings from the DHS further
support that proteinuria must be considered as an import-
ant assessment of risk for adverse CVD outcomes in indi-
viduals with T2D and their family members.
Limitations
It is unclear whether these findings are generalizable to
other ethnic groups and non-diabetic individuals. The
high rates of traditional CVD risk factors in DHS sub-
jects represent an excessive burden of co-morbid condi-
tions that contribute to risk for mortality. We attempted
to account for many of these factors in the adjusted
analyses. In addition, our assessment of kidney function
and albuminuria was based on a single measure of eGFR
and UACR; longitudinal monitoring may have provided
a more accurate assessment of risk. Despite these limita-
tions, the DHS represents a typical sample of community-
dwelling EA T2D-affected individuals in the U.S. and
provides a realistic assessment of the underlying CVD risk
that is present in such populations.
Conclusions
This study was an extension of our prior observations of
independent relationships between albuminuria and CAC,
and between CAC and mortality, and examined whether
indices of kidney disease were predictive of mortality in
EAs with T2D after considering the risk conferred by the
presence of subclinical CVD. These results provide further
support for the utility of routine clinical indices of kidney
function and proteinuria in the prediction of mortality, in-
dependent from subclinical CVD and in the absence of
more direct measures of CVD burden. As UACR is a
modifiable risk factor and treatments exist for slowing the
rate of eGFR decline, this information is clinically useful
for risk stratification along with management of trad-
itional CVD risk factors in EA T2D-affected individuals.Additional file
Additional file 1: Cumulative incidence curves for all-cause
mortality and CVD-mortality, results for T2D-only restricted
analyses and area under the curve analysis for all-cause and CVD-
mortality prediction.Abbreviations
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